A single-center, prospective, observational clinical study to predict sensitivity to neoadjuvant therapy for locally advanced rectal cancer based on the structure and distribution of intestinal flora

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400089544

Enrollment

Unknown

Registered

2024-09-10

Start date

2024-09-11

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Experimental group:None

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-75 years old, male or female; 2. Locally advanced rectal cancer patients to be treated with neoadjuvant therapy; 3. The patient knows and voluntarily signs the informed consent, can communicate in language or in writing, and has good compliance.

Exclusion criteria

Exclusion criteria: 1. Acute or chronic inflammatory diseases or infectious diseases; 2. Have used any antibiotics, prebiotics, probiotics in the past 1 week; 3. Any situation in which the investigator believes that the participant should be excluded from the study.

Design outcomes

Primary

Measure	Time frame
Intestinal flora structure and distribution;	—

Secondary

Measure	Time frame
Number of bowel movements (times /d);Bristol Stool Scale;Liver and kidney function;Blood routine examination;Stool routine;Urinalysis;C-reactive protein;Psychiatric assessment;Nutritional status assessment;Quality of life score;Relief of gastrointestinal symptoms;	—

Countries

China

Contacts

Public ContactDening Ma

Zhejiang Cancer Hospital

madeningsdu@163.com+86 135 7578 5491

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026